VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...
The discrepancy in HPV screening rates emphasizes a need for gender affirming options for sample collections. Considering the susceptibility and infection rate of transmasculine individuals and ...
Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this ...